<PAGE>
Filed pursuant to Rule 424(b)(1)
File No. 333-76343
ALLIANCE PHARMACEUTICAL CORP.
12,000,000
SHARES OF COMMON STOCK
------------
Alliance Pharmaceutical Corp. is offering up to 12,000,000 shares of
common stock with this prospectus. Our common stock is listed and traded on the
Nasdaq National Market under the symbol "ALLP." On June 1, 1999, the last
reported sale price of the common stock on the Nasdaq National Market was $2.75
per share.
<TABLE>
<CAPTION>
Per Share Total
------------ -----------
<S> <C> <C>
Public Offering Price $2.45 $29,400,000
Placement Fees* $0.16 $ 1,911,000
Proceeds to Alliance $2.29 $27,489,000
</TABLE>
* assumes 25% of the shares will be sold to existing shareholders and 75%
will be sold to new investors.
The shares of common stock will be sold directly by Alliance.
Cruttenden Roth Incorporated will act as the placement agent in connection
with the offering. Cruttenden Roth has no commitment to buy any of the
12,000,000 shares offered. It is required only to use its best efforts to
place the shares. The offering is being made on a minimum-maximum basis and
no shares of common stock will be sold if at least 6,000,000 shares of common
stock are not sold prior to June 30, 1999. Any subscription (and the related
funds) received from affiliated purchasers of Alliance or Cruttenden Roth
will not be counted in determining whether the 6,000,000 share minimum has
been met. Neither Alliance nor Cruttenden Roth will purchase shares in the
offering. All investor funds will be deposited into an escrow account with an
escrow agent until the closing. Investors' funds not transmitted directly to
the escrow account will be received by the placement agent. The placement
agent will then promptly transmit them to the escrow account by noon the next
business day after receipt. The escrow account will bear interest at a
variable rate equal to the escrow agent's money market account rate
(currently approximately 4.3%). If, for any reason, the offering is
terminated, any funds received and interest on those funds will be returned
promptly.
If funds sufficient to purchase 6,000,000 shares are received from
investors prior to June 30, 1999, Alliance may delay the actual sale of
shares (but not later than June 30, 1999) in order to maximize the number (up
to 12,000,000) of shares it will sell in the offering.
WE URGE YOU TO READ THE "RISK FACTORS" SECTION BEGINNING ON PAGE 5 FOR
A DESCRIPTION OF RISKS ASSOCIATED WITH PURCHASING OUR COMMON STOCK THAT YOU
SHOULD CONSIDER BEFORE BUYING SHARES OF OUR COMMON STOCK.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED THESE SECURITIES OR DETERMINED THAT THIS
PROSPECTUS IS TRUTHFUL OR COMPLETE OR PASSED UPON THE ACCURACY OR ADEQUACY OF
THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
You should rely only on the information contained in this prospectus.
We have not authorized anyone to provide you with different information.
The date of this prospectus is June 2, 1999.
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
<S> <C>
Prospectus Summary................................................................... 1
Risk Factors......................................................................... 4
Incorporation of Certain Documents by Reference...................................... 10
Where You Can Find More Information.................................................. 10
Use of Proceeds...................................................................... 11
Dilution............................................................................. 11
Plan of Distribution................................................................. 12
Legal Matters........................................................................ 13
Experts.............................................................................. 13
</TABLE>
NOTE TO READERS OF THIS PROSPECTUS
We were incorporated in 1983 in New York. Our address is 3040 Science
Park Road, San Diego, California 92121. Information contained on our website
does not constitute part of this prospectus.
IMAGENT-R-, LIQUIVENT-R- and FLOGEL-R- are registered trademarks of Alliance.
OXYGENT-TM-, PULMOSPHERES-TM- and RODA-TM- are trademarks of Alliance.
<PAGE>
PROSPECTUS SUMMARY
MANY OF THE MATTERS SET FORTH IN THIS PROSPECTUS CONTAIN
FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT
COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE SET FORTH IN THIS
PROSPECTUS. WE REFER YOU TO CAUTIONARY INFORMATION CONTAINED ELSEWHERE IN
THIS PROSPECTUS AND IN OTHER DOCUMENTS WE FILE WITH THE SECURITIES AND
EXCHANGE COMMISSION FROM TIME TO TIME.
THE COMPANY
Alliance Pharmaceutical Corp. is a pharmaceutical research and
development company with three products in late-stage human (clinical)
development, each of which is designed to address a different medical need.
These products are based on our expertise with perfluorochemicals and other
technologies. Perfluorochemicals are man-made chemicals that can dissolve and
carry oxygen throughout the body, including within the lung. Perfluorochemicals
have also been shown to be useful in enhancing ultrasound images.
OXYGENT is a temporary oxygen carrier to reduce or eliminate the need
for human blood transfusions during elective surgeries where substantial blood
loss is common. OXYGENT is a "blood substitute" that uses perfluorochemicals as
raw materials, not human or animal blood. A Phase 3 study is underway in Europe
and an additional Phase 3 study is planned in the U.S. to assess whether the use
of OXYGENT can reduce the need for donor blood in surgical patients. Phase 3
studies are typically the final human studies required prior to requesting
marketing approval from a U.S. or foreign regulatory agency.
LIQUIVENT is a perfluorochemical liquid that is trickled directly into
the lungs of a patient who is being supported by a mechanical ventilator.
LIQUIVENT therapy is expected to reduce the damage resulting from prolonged use
of the ventilator, open up collapsed air sacs, assist in providing oxygen to and
removing carbon dioxide from the lungs, and flush debris from the lungs. We are
currently conducting a Phase 3 clinical study in the U.S., Canada, and Europe to
evaluate the use of LIQUIVENT for the treatment of adult patients with acute
(sudden-onset) lung injury and acute respiratory distress syndrome; however, one
or more additional studies may be required prior to filing a New Drug
Application with the FDA.
IMAGENT is a perfluorochemical-based diagnostic agent intended for use
with ultrasound diagnostic techniques to enhance real-time images of blood flow
in the blood vessels, heart, and other organs. On May 11, 1999 we announced that
two Phase 3 studies in which IMAGENT was evaluated as a contrast agent
demonstrated highly statistically significant improvement in visualization of
the walls of the heart (endocardial border delineation) compared to standard
(non-contrasted) ultrasound imaging.
In addition, we have other products in early development.
PULMOSPHERES are drug-containing hollow, porous particles that are
being developed for delivery of drugs to the lungs via traditional inhalers and
other devices. Laboratory (non-human) studies are being conducted to evaluate
the potential uses of PULMOSPHERES.
FLOGEL is a liquid/gel that is intended to reduce the occurrence of
internal adhesions (scar tissue) in patients undergoing surgeries involving
their internal organs.
1
<PAGE>
RODA is a monitor intended to provide real-time measurements of the
cardiovascular (heart and blood system) and oxygenation status of surgical
patients.
During the past 16 months we resumed responsibility for the development
and cost of OXYGENT and LIQUIVENT due to differences in priorities and clinical
development strategies with our former partners. This forced us to reallocate
our human and capital resources. We intend to seek new partners for both
products, as well as for PULMOSPHERES.
2
<PAGE>
THE OFFERING
<TABLE>
<S> <C>
Offering................................................................ 12,000,000 shares
Securities offered...................................................... Common stock, $.01 par value
Shares of common stock outstanding prior to this offering............... 34,010,049 shares (1)
Use of proceeds......................................................... Clinical trials, working capital and
general corporate purposes
</TABLE>
(1) Shares of common stock outstanding as of May 27, 1999; excludes (i)
5,290,410 shares of common stock issuable upon exercise of outstanding
stock options at a weighted average exercise price of $7.72 per share;
(ii) 1,045,523 shares of common stock issuable upon exercise of
outstanding warrants at a weighted average exercise price of $9.21 per
share; and (iii) 900,000 shares issuable upon conversion of $1,800,000
aggregate principal amount of subordinated convertible notes due 2002.
3
<PAGE>
SUMMARY FINANCIAL DATA
The following summary financial data for the three years ended June 30,
1998 are derived from the audited consolidated financial statements of Alliance.
The financial data for the nine months ended March 31, 1998 and 1999 are derived
from unaudited financial statements. The unaudited financial statements include
all adjustments, consisting of normal recurring accruals which the Company
considers necessary for a fair presentation of the financial position and
results of operations for such periods.
Operating results for the nine months ended March 31, 1999 are not
necessarily indicative of the results that may be expected for the entire year
ending June 30, 1999. The data should be read in conjunction with the
consolidated financial statements, related notes, and other financial
information incorporated by reference herein.
<TABLE>
<CAPTION>
NINE MONTHS ENDED
FISCAL YEAR ENDED JUNE 30, MARCH 31,
-------------------------- ---------
OPERATING DATA: 1996 1997 1998 1998 1999
---- ---- ---- ---- ----
(In thousands, except per share data)
<S> <C> <C> <C> <C> <C>
Total revenues.................... $ 17,323 $ 44,580 $ 21,209 $ 16,144 $ 7,169
Net loss applicable to
common shares
$(23,172) $(19,016) $(33,003) $(23,975) $(43,420)
Net loss per common share
Basic and diluted $ (0.91) $ (0.63) $ (1.04) $ (0.76) $ (1.35)
</TABLE>
<TABLE>
<CAPTION>
JUNE 30, MARCH 31,
------------------ ---------
SELECTED BALANCE SHEET DATA: 1997 1998 1999
---- ---- ----
(In thousands)
<S> <C> <C> <C>
Working capital........................................... $ 62,995 $ 48,730 $ 2,536
Total assets.............................................. 112,013 93,677 59,235
Long-term debt and other.................................. 2,871 8,921 24
Stockholders' equity...................................... 91,331 76,090 38,715
</TABLE>
4
<PAGE>
RISK FACTORS
Investing in our stock involves a high degree of risk. You should
carefully consider the following risk factors and all other information
contained in this prospectus before purchasing our stock. Any of the following
risks could materially adversely affect our business, operating results and
financial condition and could result in a complete loss of your investment.
WE HAVE A HISTORY OF OPERATING LOSSES AND LIMITED PRODUCT REVENUES AND WE MAY
NEVER BECOME PROFITABLE
We have had net operating losses since our inception and we expect such
losses to continue until we receive revenues from product sales. As of March 31,
1999, we had an accumulated deficit of $307.7 million. For the years ended June
30, 1996, 1997 and 1998, we incurred net losses of $23.2 million, $19.0 million
and $33.0 million, respectively. Our net loss for the nine months ended March
31, 1999 was $43.4 million. Substantially all of our revenues to date have come
from sources other than product sales, such as licensing fees, milestone
payments and payments to fund research and development activities under joint
development and license agreements.
WE MAY NOT BE ABLE TO OBTAIN THE ADDITIONAL FINANCING WE WILL NEED TO
COMPLETE DEVELOPMENT AND INTRODUCE PRODUCTS
The costs of our current clinical trials are high. We believe that our
existing capital resources, including expected revenues from our Schering
License Agreement for IMAGENT and investments, together with the proceeds from
this offering (assuming we sell at least $18,000,000 of common stock), will
satisfy our capital requirements through December 1999. However, we will need
additional financing to finance our business through at least the year 2000 and
possibly longer. Our future capital requirements will depend on many factors,
including:
- results of our late-stage clinical trials
- progress with pre-clinical testing
- continued scientific progress in our research and development
programs
- the time and cost involved in obtaining regulatory approvals
- changes in existing collaborative relationships
- patent costs
- competing technological and market developments
- the cost of manufacturing scale-up
Accordingly, we cannot estimate the amount that we will require, but we know
that it will be substantial.
5
<PAGE>
WE ARE CURRENTLY IN VIOLATION OF OUR BANK LOAN TERMS
We have an outstanding bank loan in the amount of $13.8 million.
That loan is secured by certain assets, including equipment and machinery.
The loan requires us to have at all times cash, cash equivalents and
receivables of at least $25 million. Our cash, cash equivalents and
receivables are below $25 million. Under our agreement, the bank may demand
that we pay all of our loan in full or it may take possession of the assets
that secure the loan. If we are forced to pay off our loan with existing
cash, we may have to reduce, delay or terminate some of our development
efforts and would be forced to sell assets, including technology, to raise
capital. If we raise $18 million in this offering, the bank has agreed to
waive the violation and it will reduce the cash covenant to $10 million ($5
million of which will be held by the bank as collateral). The bank has taken
a lien on some of our patents and we have agreed to restructure the loan
payments to increase principal payments. The bank has also been given a
warrant to purchase 180,000 shares of our common stock at an exercise price
of $2.88 per share.
FAILURE TO LICENSE OUR PRODUCTS COULD SERIOUSLY HINDER OUR ABILITY TO FURTHER
DEVELOP OUR PRODUCTS AND MARKET THEM SUCCESSFULLY
If we do not negotiate acceptable collaborative arrangements for our
principal products, we will lack the funds to further develop them. We do not
have internal marketing and sales capabilities and will need to rely on
collaborative partners to market and sell any products that we may successfully
develop. Even if we find collaborative partners, we may not be able to
completely control the amount and timing of resources our collaborative partners
will devote to these activities. We intend to seek collaborative arrangements
for Oxygent, LIQUIVENT and PULMOSPHERES to help cover the cost of development,
but we do not know whether we will be successful. If we cannot find
collaborative relationships or other sources of financing we may not be able to
continue some of our development programs and would be forced to sell assets,
including technology, to raise capital.
A TERMINATION OF THE SCHERING LICENSE AGREEMENT COULD ADVERSELY AFFECT OUR
RESEARCH, DEVELOPMENT AND, ULTIMATELY, MARKETING OF IMAGENT
We depend on Schering for development and regulatory approvals outside
the United States and for worldwide marketing of IMAGENT. As of December 30,
1998, the Schering license agreement was modified to reduce ongoing development
reimbursement, add new milestone payments and restructure the methods for
calculating royalties. The Schering license agreement may not be terminated
until September 1999; however, thereafter, it may be terminated on one month's
advance notice.
6
<PAGE>
WE ARE IN ARBITRATION WITH A FORMER PARTNER AND AN ADVERSE JUDGMENT COULD
COST MORE THAN $16.8 MILLION
In December 1997, our former partner for LIQUIVENT, Hoechst Marion
Roussel, Inc. (which we refer to as "HMR"), terminated its license agreement
with us. We regained all rights to and responsibilities for the product. In May
1998, HMR asked us to pay it up to $7.5 million, payable in cash or stock. On
September 25, 1998, we received a demand for arbitration from HMR, claiming up
to $16.8 million, plus interest and punitive damages, in connection with the
termination of the HMR license agreement. We have filed a counterclaim against
HMR. We do not believe its claim is valid. We intend to contest HMR's claim and
believe that the ultimate resolution will not have a material adverse effect on
our business. However, if we do not prevail on the claim, an adverse judgment
would take away substantial financial resources from our development programs,
adversely impacting our ability to finance our continuing operations.
IF WE DO NOT OBTAIN GOVERNMENTAL APPROVALS FOR OUR PRODUCTS, WE WILL BE
UNABLE TO MARKET THEM
We will not be able to commercialize our products until we have
acceptable clinical trial results and regulatory approval from the FDA and
foreign regulatory authorities. The FDA and other regulatory authorities require
that the safety and efficacy of a drug be supported by results from adequate and
well-controlled clinical trials before approval for commercial sale. If the
results of the clinical trials of our products do not demonstrate that they are
safe and effective, we will not be able to submit to the FDA a New Drug
Application or other relevant applications for pre-market approval. Further, the
results of preclinical testing and initial clinical trials do not necessarily
predict how safe and effective a product will be when it is evaluated in
large-scale Phase 3 clinical trials. It is possible that unacceptable side
effects may be discovered at any time. A number of companies have suffered
significant setbacks in advanced clinical trials, despite promising results in
earlier trials.
Even if we believe the clinical trials demonstrate the safety and
efficacy of a product, the FDA and other regulatory authorities may not accept
our assessment of the results. The FDA has required other companies involved in
the development of blood substitutes to increase the size of their Phase 3
trials, extending the time and cost to complete the trials. In any case, in
order to demonstrate the safety and efficacy of the products we may have to
conduct additional clinical trials beyond those currently planned. The process
of obtaining regulatory clearances or approvals is costly and time-consuming.
As of the date of this prospectus, we have not agreed with the FDA on
the design for the U.S. Phase 3 clinical trial for OXYGENT.
7
<PAGE>
DELAYS IN THE COMPLETION OF OUR CLINICAL TRIALS COULD INCREASE OUR COSTS
We cannot predict how long our preclinical and clinical trials will
take or whether they will be successful. The rate of completion of the clinical
trials for our products depends on many factors, including obtaining adequate
clinical supplies and the rate of patient recruitment. Patient recruitment is a
function of many factors, including the size of the patient population, the
proximity of patients to clinical sites, and the eligibility criteria for
patients who may enroll in the trial. We may experience increased costs, program
delays, or both, if there are delays in patient enrollment in the clinical
trials.
WE WILL BE UNABLE TO MANUFACTURE OUR PRODUCTS IF WE DO NOT RECEIVE FDA APPROVAL
While we believe that we can produce materials for clinical trials and
the initial market launch for OXYGENT and IMAGENT at our existing San Diego
facilities and for LIQUIVENT at our Otisville, New York facility, we will need
FDA approval in order to do so. We do not know whether the FDA will determine
that our facilities comply with Good Manufacturing Practices. A delay in FDA
approval of our manufacturing facilities would delay the marketing of our
products.
IF WE CANNOT PROTECT OUR PATENTS AND PROPRIETARY TECHNOLOGY WE WILL BE UNABLE TO
SUCCESSFULLY MANUFACTURE AND MARKET OUR PRODUCTS
We believe that our success will depend largely on our ability to
obtain and maintain patent protection for our own inventions, and to license the
use of patents owned by third parties. We have obtained patents covering certain
intermediate and high concentration PFC emulsions, patents related to liquid
ventilation, and patents covering certain stabilized microbubble compositions,
as well as other patents. We have filed, and when appropriate will file, other
patent applications with respect to our products and processes in the United
States and in foreign countries. We cannot assure you, however, that we will
develop any additional products and processes that will be patentable or that
any additional patents will be issued to us. It is possible that any of our
patents or any patents licensed to us may be challenged successfully. It is also
possible that we may unintentionally infringe on patents of third parties, or
that we may have to alter our products or manufacturing processes to take into
account the patents of third parties and this may cause delays in product
development. Further, we cannot assure that we will be able to alter our
products or manufacturing processes to avoid third party patents, in which case
we may have to terminate the development or commercialization of a product or
pay royalties to the holders of the patents. Litigation, which could result in a
substantial cost to us, may be necessary to enforce any patents we own and/or to
determine the scope and validity of others' proprietary rights. We also attempt
to protect our proprietary products and processes by relying on trade secret
laws and non-disclosure and confidentiality agreements with our employees and
certain other persons who have access to our products or processes. It is
possible that others will develop such products or processes independently or
obtain access to such products or processes. Our competitive position may be
affected adversely if others develop or obtain products or processes similar to
ours.
In particular, with respect to ultrasound contrast imaging patents,
there are several companies with issued patents and other patent applications in
process. Many of these patents overlap each other, and it will take several
years to clarify which ones are valid and enforceable. Although we believe we
have the right to manufacture, use and sell IMAGENT once it is approved, it is
possible that we may need to license rights under patents owned by others, and
that such rights may not be available. Other companies may well find that their
current or future activities violate our patents. We believe certain companies
have obtained patents to which they are not entitled under U.S. law, and have
requested
8
<PAGE>
patent interference proceedings in the U.S. Patent Office to resolve those
issues.
WE WILL NOT BE ABLE TO DEVELOP OR MANUFACTURE OUR PRODUCTS IF WE ARE UNABLE
TO OBTAIN THE NECESSARY RAW MATERIALS
Some of the raw materials for our products are available from single
sources. At times, one or more of these raw materials may not be available or
may be available only in limited quantities. Our ability to develop our products
could be materially adversely affected if sufficient supplies of raw materials
are not available. We are currently negotiating with some of these suppliers for
long-term supply contracts for raw materials; however, we do not know whether we
will be able to obtain commitments for a long-term supply of these raw materials
on acceptable terms.
UNFORESEEN TECHNOLOGICAL AND SCIENTIFIC PROBLEMS OR THIRD PARTY DEVELOPMENT
MAY DELAY OR PREVENT MARKETING
We or our collaborative partners may encounter unforeseen technological
or scientific problems, including adverse side effects, which may force us to
abandon or substantially change the plan of development of a specific product or
process. A technological change or product development by others may also have a
significant adverse effect on our operations.
THE LACK OR INADEQUACY OF THIRD-PARTY REIMBURSEMENT FOR OUR PRODUCTS WOULD HAVE
A MATERIAL ADVERSE EFFECT ON OUR OPERATIONS
Our ability to commercialize our products successfully will depend in
part on the extent to which the cost of the products and related treatment will
be reimbursed by government authorities, private health insurers and other
organizations, such as HMOs. Third party payors are increasingly challenging the
prices charged for medical products and services. Also, the trend toward managed
healthcare in the United States, the growth of healthcare organizations such as
HMOs, and legislative proposals to reform healthcare and government insurance
programs could significantly influence the purchase of healthcare services and
products, resulting in lower prices and reducing demand for our products. The
cost containment measures that healthcare providers are instituting and any
healthcare reform could affect our ability to sell our products by not allowing
us to make a profit on sales of products. We cannot assure you that full or
partial reimbursement in the United States or foreign countries will be
available for any of our products. If reimbursements are not available or
sufficient, we may not be able to sell our products. We cannot forecast what
additional legislation or regulation relating to the healthcare industry or
third-party coverage and reimbursement may be enacted in the future, or what
effect the legislation or regulation would have on our business.
MANY OF OUR EXISTING OR POTENTIAL COMPETITORS HAVE SUBSTANTIALLY GREATER
RESOURCES AND MAY BE BETTER EQUIPPED TO DEVELOP, MANUFACTURE AND MARKET PRODUCTS
SIMILAR TO OURS
We may not be able to compete successfully in developing and marketing
our products. There are many pharmaceutical companies, biotechnology companies,
public and private universities, and research organizations actively engaged in
research and development of products that compete with our products. These
companies have more resources and may develop and introduce products and
processes competitive with or superior to ours. In addition, our products and
technologies may be rendered uncompetitive or obsolete by the development of
other technologies or products that have an entirely different approach or means
of accomplishing the same purposes.
9
<PAGE>
OUR PRODUCTS AND THE PROCESSES WE USE COULD EXPOSE ALLIANCE TO SUBSTANTIAL
LIABILITY
Product liability could arise from claims by users of our products or
of products manufactured by processes we developed, or from manufacturers or
others selling our products, either directly or as a component of other
products. Our product liability insurance coverage may not be adequate.
WE MAY ISSUE ADDITIONAL PREFERRED STOCK, THE TERMS OF WHICH COULD ADVERSELY
AFFECT OUR COMMON STOCK
Our Board of Directors has the authority to issue up to an additional
3 million shares of preferred stock and may determine the rights, preferences,
privileges and restrictions of such shares without any further vote or action by
the shareholders. The possible issuance of preferred stock could have the effect
of delaying, deferring or preventing a change in control of Alliance. The
conversion and other features of any series of preferred stock may also limit
the price that investors might be willing to pay in the future for shares of our
common stock.
THE SUBSTANTIAL NUMBER OF OUR SHARES THAT ARE ELIGIBLE FOR FUTURE SALE COULD
ADVERSELY AFFECT OUR ABILITY TO FIND NEW EQUITY INVESTORS
As of May 27, 1999, 7,235,933 shares of our common stock (or 17.5%
of the total number of shares outstanding on a fully diluted basis) were
issuable upon the exercise of outstanding options and warrants. Also, over a
period of approximately four years, we may issue an indeterminate number of
additional shares of our common stock to the former shareholders of MDV
Technologies, Inc., a company we acquired in 1996. The existence of such
warrants, options and convertible securities, as well as certain registration
rights, may adversely affect the terms on which we may obtain additional
equity financing and the aftermarket trading of our stock. The holders of the
outstanding warrants and options are likely to exercise their securities at a
time when we would otherwise be able to obtain capital on terms more
favorable than those provided by the exercise or conversion prices thereof.
10
<PAGE>
IF OUR COMPUTER SYSTEMS OR THE COMPUTER SYSTEMS OF ANY OF OUR SUPPLIERS OR
COLLABORATIVE PARTNERS ARE NOT YEAR 2000 COMPLIANT OUR OPERATIONS COULD BE
INTERRUPTED
Many currently installed operating systems and software products are
coded only to accept two digit entries in the date code field. Consequently,
they are unable to distinguish 21st century dates from 20th century dates. As a
result, the computer systems and software used by many companies may need to be
upgraded to prevent problems that would result from misreading the entries in
the date code field. Failure to correct systems to become "Year 2000 compliant"
may result in systems failures or miscalculations causing disruptions of
operations, including, among other things, a temporary inability to process
data, send invoices or engage in similar normal business activities.
We are currently reviewing the potential impact of Year 2000 issues on
our business and attempting to mitigate or eliminate those issues. The primary
risks to us are those of business continuity. We are determining which equipment
we own needs to be replaced. We have also begun communicating with our
significant suppliers, financial institutions, insurance companies and other
parties that provide us significant services, including clinical trial sites, to
determine whether they anticipate Year 2000 problems in their operations. If we
or our significant vendors or suppliers are unable to become Year 2000 compliant
in time, this could delay our product development efforts and have a material
adverse effect on our ability to continue our operations.
11
<PAGE>
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus may contain forward-looking statements regarding our
plans, expectations, estimates and beliefs. Our actual results could differ
materially from those discussed in, or implied by, these forward-looking
statements. Forward-looking statements are identified by words such as
"believe," "anticipate," "expect," "intend," "plan," "will," "may," and other
similar expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or circumstances are
forward-looking statements. Forward-looking statements in this document
include, but are not necessarily limited to, those relating to:
- our ability to raise additional capital when needed
- obtaining, or our ability to obtain, approval by the FDA
and other regulatory authorities for certain products
- our ability or capacity to manufacture, market and distribute
our products
- uncertainty of market acceptance of our products
- our ability to obtain patents for our products and
technologies
- relationships with and abilities of important suppliers
and business partners
- the development of new products and enhanced versions of
existing products
Factors that cause actual results or conditions to differ from those anticipated
by these and other forward-looking statements include those more fully described
in the risk factors section and elsewhere in this prospectus. We are not
obligated to update or revise these forward-looking statements to reflect new
events or circumstances.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
We file annual, quarterly and special reports, proxy statements and
other information with the SEC. You may read and copy any documents we file at
the SEC's public reference room in Washington, D.C. at 450 Fifth Street, N.W.,
Washington, D.C. 20549, or in the public reference rooms located in New York,
New York and Chicago, Illinois. Please call the SEC at 1-800-SEC-0330 for
further information on the public reference rooms. Our SEC filings are also
available to the public at the SEC's website at http://www.sec.gov.
The SEC allows us to "incorporate by reference" the information we
file with it, which means that we can disclose important information to you
by referring you to those documents. The information incorporated by
reference is considered to be part of this prospectus, and information we
later file with the SEC will automatically update and supersede this
information. We incorporate by reference the documents listed below and any
future filings we will make with the SEC under Sections 13(a), 13(c), 14 and
15(d) of the Exchange Act:
1. Annual Report on Form 10-K/A for the fiscal year ended June 30,
1998;
2. Quarterly Report on Form 10-Q for the quarters ended September 30,
1998, December 31, 1998 and March 31, 1999; and
3. Registration Statement on Form 8-A, dated October 25, 1984.
12
<PAGE>
We will provide without charge to any person to whom this prospectus is
delivered, upon written or oral request of such person, a copy of any or all of
the documents which have been incorporated by reference in this prospectus.
Requests for copies should be directed to Lloyd Rowland, Secretary and General
Counsel, Alliance Pharmaceutical Corp., 3040 Science Park Road, San Diego,
California 92121, telephone (619) 558-4300.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on Form S-3 (the
"Registration Statement") under the Securities Act, with respect to the
shares offered in this prospectus. This prospectus does not contain all the
information set forth in the Registration Statement and exhibits thereto,
certain portions of which have been omitted as permitted by the rules and
regulations of the SEC. Copies of the Registration Statement (including the
omitted portions) are available from the SEC upon payment of prescribed
rates. For further information, reference is made to the Registration
Statement and the exhibits filed therewith. Statements contained in this
prospectus or the Registration Statement relating to the contents of any
contract or other document filed as an exhibit to the Registration Statement
are not necessarily complete, and in each instance are qualified in all
respects by the full text of such contract or document.
You should rely only on the information or representations provided in
this prospectus or incorporated by reference. We have not authorized anyone else
to provide you with different information. The selling stockholders have agreed
not to make an offer of the shares of our common stock in any state where the
offer is not permitted. You should not assume that the information in this
prospectus is accurate as of any date other than the date on the cover page.
13
<PAGE>
USE OF PROCEEDS
We plan to use the majority of the net proceeds from this offering to
fund late-stage clinical trials of OXYGENT and LIQUIVENT and to prepare a New
Drug Application filing package for IMAGENT. The balance of the net proceeds
will be used for working capital and other general corporate purposes and
limited research and development for PULMOSPHERES. The amounts actually expended
for each purpose and the timing of such expenditures may vary significantly
depending upon various factors including, but not limited to, the results and
timing of our clinical development, the launch of new products, governmental or
regulatory changes, the role of corporate partners and technological advances
and competition by others. In addition, there can be no assurance that any
product developed or introduced by us will be commercialized or that funds will
be sufficient to develop successful products.
We expect to use all of the net proceeds from this offering for the
purposes described above, and we will require substantial additional funds in
the future in order to continue our development programs and to manufacture and
market any future products. We anticipate that existing cash balances and
interest income thereon, together with the net proceeds of this offering will be
adequate to satisfy our capital requirements through December 1999 (assuming we
raise at least $18,000,000). Pending such uses, we intend to invest the net
proceeds of this offering in short-term, investment grade securities.
On May 20, 1999 we privately placed $1.8 million principal amount of
6% convertible subordinated notes due 2002 and warrants to purchase up to
300,000 shares of common stock for an aggregate purchase price of
approximately $1.8 million. The conversion price of the notes is $2 per
share; the exercise price of the warrants is $2.50 per share. We used the
proceeds from this private placement to restore $1.8 million of our working
capital used to repurchase 20,707 of the outstanding shares of the Series E-1
Preferred Stock. All of the remaining shares of Series E-1 Preferred Stock
were converted at the same time at a conversion price of $2.46 per share.
14
<PAGE>
DILUTION
As of March 31, 1999, the net tangible book value applicable to
common shareholders of Alliance was approximately $13.8 million, or $.42 per
share. "Net tangible book value per share" represents the amount of total
tangible assets of the Company reduced by the total liabilities and total
liquidation preferences of preferred stock, and divided by the number of
shares of common stock outstanding. After giving effect to the sale of all
the 12,000,000 shares of common stock offered in this offering at the public
offering price of $2.45 per share and the effect of the conversion and
repurchase of the Series E-1 Preferred Stock, the pro forma net tangible book
value of the common stock as of March 31, 1999 (after deducting the estimated
placement fees and estimated expenses of this offering) would have been
approximately $42.1 million, or $0.92 per share. This represents an immediate
increase in net tangible book value of $0.50 per share to existing
shareholders and an immediate dilution of $1.53 per share to new investors
purchasing shares of common stock in this offering. "Dilution per share"
represents the difference between the price per share of common stock paid by
the new investors in this offering and the net tangible book value per share
at March 31, 1999 as adjusted to give effect to the sale of 12,000,000 shares
in this offering and the conversion and repurchase of the Series E-1
Preferred Stock.
The following table illustrates the dilution per share taking into
account estimated expenses of this offering(1):
<TABLE>
<S> <C>
Public offering price per share $2.45
- ---------------------------------------------------------------------------------------
Net tangible book value per share as of December 31, 1998 $0.42
- ---------------------------------------------------------------------------------------
Increase to present shareholders attributable to this offering $0.50
- ---------------------------------------------------------------------------------------
Pro forma net tangible book value per share after this offering $0.92
- ---------------------------------------------------------------------------------------
Dilution to investors in this offering (2)(3) $1.53
- ---------------------------------------------------------------------------------------
</TABLE>
(1) For purposes of calculating expenses we estimated the placement agent's fee
at an average of 6.5% of the proceeds received.
(2) On May 19, 1999, we converted 31,456 shares of Series E-1 Preferred Stock
into 767,219 shares of common stock and repurchased 20,707 shares of Series
E-1 Preferred Stock for $2.2 million in cash.
(3) For purposes of calculating the dilution table, we did not include the
effects of the issuance of $1.8 million in convertible debentures on May 20,
1999.
To the extent fewer than 12,000,000 shares are sold in this offering, the
dilution to new investors would be increased.
15
<PAGE>
PLAN OF DISTRIBUTION
We cannot be certain that we will be able to sell all of the shares
offered, and it is possible that we will close this offering for less than the
12,000,000 shares being offered.
All investor funds will be deposited into an escrow account
established on the investors' behalf with City National Bank pending
effectiveness of the registration statement and issuance of the shares.
Subscriber checks will be made payable to the escrow agent. Investors' funds
not transmitted directly to the escrow account will be received by the
placement agent. The placement agent will then promptly transmit them to the
escrow account by noon the next business day after receipt. Alliance will not
receive any investor funds prior to the issuance of the shares. No investor
funds may be accepted for deposit in escrow until the registration statement
is declared effective. We will deposit the shares with the Depository Trust
Company upon receiving a notice from the escrow agent. The shares will then
be credited to the respective accounts of the investors.
The offering is being made on a minimum-maximum basis and no shares
of common stock will be sold if at least 6,000,000 shares are not sold prior
to June 30, 1999. Neither Alliance nor the placement agent will purchase
shares in the offering. Affiliated purchasers of Alliance or the placement
agent are permitted to do so; however, any subscription (and the related
funds) received from affiliated purchasers of Alliance or the placement agent
will not be counted in determining whether the 6,000,000 share minimum has
been met. If, for any reason, the offering is terminated, then all funds that
were deposited into escrow will be returned to investors.
Cruttenden Roth Incorporated has agreed to act as placement agent in
connection with the offering and will use its best efforts to place the shares.
Cruttenden Roth has no obligation to buy any shares in the offering.
We have agreed to pay Cruttenden Roth a fee of 2% of the proceeds we
receive from existing shareholders who purchase shares in this offering and
8% of the proceeds we receive from new investors in this offering. In
addition, we will issue to Cruttenden Roth at the closing of the offering,
warrants to purchase common stock in an amount of 8% of the shares of common
stock sold in this offering to investors solicited by Cruttenden Roth. The
warrants will be exercisable for a period of five years from the effective
date of the offering with an exercise price equal to 150% of the public
offering price per share. The warrants will bear a legend stating that they
will not be sold, transferred, pledged, assigned or hypothecated for a period
of one year from the effective date of the offering except to officers (not
directors) of Crutenden Roth. We also agreed to reimburse Cruttenden Roth for
expenses that it incurs in connection with the offering up to $20,000 and to
indemnify Cruttenden Roth against certain liabilities under the Securities
Act. The Chairman and Chief Executive Officer of Cruttenden Roth is the
brother of both the President and the Chief Executive Officer of Alliance.
LEGAL MATTERS
The legality of the issuance of the shares of common stock offered
hereby will be passed upon for Alliance by Stroock & Stroock & Lavan LLP.
EXPERTS
Ernst & Young LLP, independent auditors, have audited our consolidated
financial statements included in our annual report on Form 10K/A for the year
ended June 30, 1998, as set forth in their report (which contains an explanatory
paragraph describing conditions that raise substantial doubt about the Company's
ability to continue as a going concern as described in Note 1 to the
consolidated financial statements), which is incorporated by reference in this
prospectus and elsewhere in the registration statement. Our financial statements
are incorporated by reference in reliance on Ernst & Young LLP's report, given
on their authority as experts in accounting and auditing.
16
